Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Immune profiling and quantitative analysis decipher the clinical role of immune checkpoint expression in the tumor immune microenvironment of DLBCL.

Xu-Monette Z, Xiao M, Au Q, Padmanabhan R, Xu B, Hoe N, Rodriguez-Perales S, Torres-Ruiz R, Manyam G, Visco C, Miao Y, Tan X, Zhang H, Tzankov A, Wang J, Dybkaer K, Tam W, You H, Bhagat G, Hsi ED, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, van Krieken JH, Winter JN, Westin JR, Pham LV, Medeiros LJ, Rassidakis GZ, Li Y, Freeman GJ, Young KH.

Cancer Immunol Res. 2019 Feb 11. pii: canimm.0439.2018. doi: 10.1158/2326-6066.CIR-18-0439. [Epub ahead of print]

PMID:
30745366
2.

Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis.

Jespersen DS, Schönherz AA, Due H, Bøgsted M, Sondergaard TE, Dybkær K.

Sci Rep. 2019 Jan 23;9(1):335. doi: 10.1038/s41598-018-36680-x.

3.

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.

Li L, Sun R, Miao Y, Tran T, Adams L, Roscoe N, Xu B, Manyam GC, Tan X, Zhang H, Xiao M, Tzankov A, Visco C, Dybkaer K, Bhagat G, Tam W, Hsi ED, van Krieken JH, You H, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Zhang M, Winter JN, Medeiros LJ, Rassidakis GZ, Vaupel CA, Li Y, Dakappagari N, Xu-Monette ZY, Young KH.

Mod Pathol. 2019 Jan 21. doi: 10.1038/s41379-018-0193-5. [Epub ahead of print]

PMID:
30666052
4.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, Johnson D, Bertsch U, Broyl A, van Duin M, Shah R, Johansen P, Nørgaard MA, Samworth RJ, Sonneveld P, Goldschmidt H, Morgan GJ, Orfao A, Munshi N, Johnson HE, El-Galaly T, Dybkær K, Bøgsted M.

Blood Adv. 2018 Sep 25;2(18):2400-2411. doi: 10.1182/bloodadvances.2018018564.

5.

A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.

Michaelsen TY, Richter J, Brøndum RF, Klapper W, Johnsen HE, Albertsen M, Dybkær K, Bøgsted M.

Blood Adv. 2018 Jul 10;2(13):1542-1546. doi: 10.1182/bloodadvances.2018017988.

6.

Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.

Wang X, Cao X, Sun R, Tang C, Tzankov A, Zhang J, Manyam GC, Xiao M, Miao Y, Jabbar K, Tan X, Pang Y, Visco C, Xie Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WWL, van Krieken JH, Huh J, Ponzoni M, Ferreri AJM, Møller MB, Parsons BM, Winter JN, Piris MA, Li S, Miranda RN, Medeiros LJ, Li Y, Xu-Monette ZY, Young KH.

Neoplasia. 2018 Jun;20(6):574-593. doi: 10.1016/j.neo.2018.03.002. Epub 2018 May 4.

7.

Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study.

Øvlisen AK, Oest A, Bendtsen MD, Bæch J, Johansen P, Lynggaard LS, Mølle I, Mortensen TB, Weber D, Ertner G, Schöllkopf C, Thomassen JQ, Nielsen OJ, Østgård LSG, Bøgsted M, Dybkær K, Johnsen HE, Severinsen MT.

Blood Adv. 2018 Mar 13;2(5):559-564. doi: 10.1182/bloodadvances.2017007393.

8.

Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study.

Nørgaard CH, Jakobsen LH, Gentles AJ, Dybkær K, El-Galaly TC, Bødker JS, Schmitz A, Johansen P, Herold T, Spiekermann K, Brown JR, Klitgaard JL, Johnsen HE, Bøgsted M.

PLoS One. 2018 Mar 7;13(3):e0193249. doi: 10.1371/journal.pone.0193249. eCollection 2018.

9.

Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma.

Marcussen M, Sønderkær M, Bødker JS, Andersen M, Nielsen S, Vesteghem C, Christiansen I, Bergmann OJ, Bøgsted M, Dybkær K, Vyberg M, Johnsen HE.

PLoS One. 2018 Jan 16;13(1):e0190709. doi: 10.1371/journal.pone.0190709. eCollection 2018.

10.

A systematic review of molecular responses to cancer therapy in normal human mucosa.

Marcussen M, Skrubbeltrang C, Bødker JS, Christiansen I, Bøgsted M, Dybkær K, Bergmann OJ, Johnsen HE.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Oct;124(4):355-366. doi: 10.1016/j.oooo.2017.08.002. Epub 2017 Aug 15. Review.

PMID:
29042035
11.

Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

Visco C, Wang J, Tisi MC, Deng L, D'Amore ESG, Tzankov A, Montes-Moreno S, Dybkær K, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Piris MA, Medeiros LJ, Xu-Monette ZY, Young KH.

Br J Cancer. 2017 Nov 21;117(11):1685-1688. doi: 10.1038/bjc.2017.345. Epub 2017 Sep 26.

12.

HPV16 E6 and E7 Upregulate Interferon-Induced Antiviral Response Genes ISG15 and IFIT1 in Human Trophoblast Cells.

Ambühl LMM, Villadsen AB, Baandrup U, Dybkær K, Sørensen S.

Pathogens. 2017 Sep 3;6(3). pii: E40. doi: 10.3390/pathogens6030040.

13.

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, Visco C, Bhagat G, Wang J, Dybkaer K, Tam W, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Møller MB, Winter JN, Piris MA, Fayad L, Liu Y, Song Y, Orlowski RZ, Kantarjian H, Medeiros LJ, Li Y, Cortes J, Young KH.

Leukemia. 2018 Feb;32(2):353-363. doi: 10.1038/leu.2017.222. Epub 2017 Jul 12.

14.

Human papillomavirus infects placental trophoblast and Hofbauer cells, but appears not to play a causal role in miscarriage and preterm labor.

Ambühl LMM, Leonhard AK, Widen Zakhary C, Jørgensen A, Blaakaer J, Dybkaer K, Baandrup U, Uldbjerg N, Sørensen S.

Acta Obstet Gynecol Scand. 2017 Oct;96(10):1188-1196. doi: 10.1111/aogs.13190. Epub 2017 Aug 14.

PMID:
28699189
15.

AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, Visco C, Wang J, Montes-Moreno S, Dybkær K, Tam W, Bhagat G, Hsi ED, van Krieken JH, Ponzoni M, Ferreri AJM, Wang S, Møller MB, Piris MA, Medeiros LJ, Li Y, Pham LV, Young KH.

Am J Pathol. 2017 Aug;187(8):1700-1716. doi: 10.1016/j.ajpath.2017.04.009. Epub 2017 Jun 13.

16.

Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.

Bech RS, Nielsen KL, Larsen TS, Bentzen HH, Lynggaard LS, Do TH, Braendstrup P, Brady J, Mikhaeel NG, Dybkaer K, Johnsen HE, Jensen P, Bøgsted M, El-Galaly TC.

Br J Haematol. 2018 Jul;182(2):297-301. doi: 10.1111/bjh.14775. Epub 2017 May 23. No abstract available.

PMID:
28542714
17.

Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival.

Nielsen KR, Rodrigo-Domingo M, Steffensen R, Baech J, Bergkvist KS, Oosterhof L, Schmitz A, Bødker JS, Johansen P, Vogel U, Vangsted A, Dybkær K, Bøgsted M, Johnsen HE.

Leuk Lymphoma. 2017 Nov;58(11):2695-2704. doi: 10.1080/10428194.2017.1306643. Epub 2017 Apr 9.

PMID:
28393658
18.

Molecular classification of tissue from a transformed non-Hogkin's lymphoma case with unexpected long-time remission.

Bødker JS, Severinsen MT, El-Galaly TC, Brøndum RF, Laursen MB, Falgreen S, Nyegaard M, Schmitz A, Jakobsen LH, Schönherz AA, Due H, Reinholdt L, Bøgsted M, Dybkær K, Johnsen HE.

Exp Hematol Oncol. 2017 Jan 11;6:3. doi: 10.1186/s40164-016-0063-0. eCollection 2017.

19.

Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa.

Marcussen M, Bødker JS, Christensen HS, Johansen P, Nielsen S, Christiansen I, Bergmann OJ, Bøgsted M, Dybkær K, Vyberg M, Johnsen HE.

PLoS One. 2017 Jan 4;12(1):e0169286. doi: 10.1371/journal.pone.0169286. eCollection 2017.

20.

RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.

Zhang M, Xu-Monette ZY, Li L, Manyam GC, Visco C, Tzankov A, Wang J, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Han van Krieken J, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Pham LV, Young KH.

Aging (Albany NY). 2016 Dec 8;8(12):3321-3340. doi: 10.18632/aging.101121.

21.

The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.

Haematologica. 2016 Dec;101(12):1451-1459. Epub 2016 Nov 10. Review.

22.

Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.

Bendtsen MD, Munksgaard PS, Severinsen MT, Bekric E, Brieghel C, Nielsen KB, Brown PN, Dybkaer K, Johnsen HE, Bøgsted M, El-Galaly TC.

Eur J Haematol. 2017 Apr;98(4):355-362. doi: 10.1111/ejh.12835. Epub 2017 Jan 31.

PMID:
27893172
23.

Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH.

Blood. 2016 Dec 29;128(26):3083-3100. doi: 10.1182/blood-2016-05-715094. Epub 2016 Oct 19.

24.

hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine.

Falgreen S, Ellern Bilgrau A, Brøndum RF, Hjort Jakobsen L, Have J, Lindblad Nielsen K, El-Galaly TC, Bødker JS, Schmitz A, H Young K, Johnsen HE, Dybkær K, Bøgsted M.

PLoS One. 2016 Oct 4;11(10):e0163711. doi: 10.1371/journal.pone.0163711. eCollection 2016.

25.

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma.

Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, Bhagat G, Zhang S, Pasqualucci L, Visco C, Dybkaer K, Chiu A, Orazi A, Zu Y, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Winter JN, Piris MA, Westin J, Fowler N, Miranda RN, Ok CY, Li Y, Li J, Medeiros LJ, Young KH.

Leukemia. 2017 Mar;31(3):625-636. doi: 10.1038/leu.2016.243. Epub 2016 Aug 29.

26.

The CXCR4 antagonist plerixafor enhances the effect of rituximab in diffuse large B-cell lymphoma cell lines.

Reinholdt L, Laursen MB, Schmitz A, Bødker JS, Jakobsen LH, Bøgsted M, Johnsen HE, Dybkær K.

Biomark Res. 2016 Jun 14;4:12. doi: 10.1186/s40364-016-0067-2. eCollection 2016.

27.

Characterization of memory B cells from thymus and its impact for DLBCL classification.

Bergkvist KS, Nørgaard MA, Bøgsted M, Schmitz A, Nyegaard M, Gaihede M, Bæch J, Grønholdt ML, Jensen FS, Johansen P, Urup T, El-Galaly TC, Madsen J, Bødker JS, Dybkær K, Johnsen HE.

Exp Hematol. 2016 Oct;44(10):982-990.e11. doi: 10.1016/j.exphem.2016.06.001. Epub 2016 Jun 11.

PMID:
27297329
28.

miR-155 as a Biomarker in B-Cell Malignancies.

Due H, Svendsen P, Bødker JS, Schmitz A, Bøgsted M, Johnsen HE, El-Galaly TC, Roug AS, Dybkær K.

Biomed Res Int. 2016;2016:9513037. doi: 10.1155/2016/9513037. Epub 2016 May 16. Review.

29.

Human Papillomavirus Infection as a Possible Cause of Spontaneous Abortion and Spontaneous Preterm Delivery.

Ambühl LM, Baandrup U, Dybkær K, Blaakær J, Uldbjerg N, Sørensen S.

Infect Dis Obstet Gynecol. 2016;2016:3086036. doi: 10.1155/2016/3086036. Epub 2016 Mar 27. Review.

30.

Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates.

Bilgrau AE, Falgreen S, Petersen A, Kjeldsen MK, Bødker JS, Johnsen HE, Dybkær K, Bøgsted M.

BMC Bioinformatics. 2016 Apr 11;17:159. doi: 10.1186/s12859-016-0997-6.

31.

Anti-Apoptotic Effects of Lentiviral Vector Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells.

Ranjbar B, Krogh LB, Laursen MB, Primo MN, Marques SC, Dybkær K, Mikkelsen JG.

PLoS One. 2016 Apr 5;11(4):e0153069. doi: 10.1371/journal.pone.0153069. eCollection 2016.

32.

Blood on the tracks - toward precision medicine.

Johnsen HE, El-Galaly TC, Dybkær K, Bøgsted M.

Leuk Lymphoma. 2016 Aug;57(8):1753-4. doi: 10.3109/10428194.2016.1154962. Epub 2016 Mar 21. No abstract available.

PMID:
26998891
33.

Alternative pre-mRNA splicing leads to potential biomarkers in diffuse large B-cell lymphoma - a systematic review.

Østergaard Poulsen M, Krogh Jørgensen L, Sørensen S, Falgreen S, Støve Bødker JS, Bach Laursen M, Schmitz A, Johnsen HE, Dybkær K, Bøgsted M.

Dan Med J. 2016 Mar;63(3). pii: A5206. Review.

PMID:
26931194
34.

Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.

Xu-Monette ZY, Deng Q, Manyam GC, Tzankov A, Li L, Xia Y, Wang XX, Zou D, Visco C, Dybkær K, Li J, Zhang L, Liang H, Montes-Moreno S, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Wang SA, Miranda RN, Piris MA, Winter JN, Medeiros LJ, Li Y, Young KH.

Clin Cancer Res. 2016 Jul 15;22(14):3593-605. doi: 10.1158/1078-0432.CCR-15-2296. Epub 2016 Feb 29.

35.

p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.

Xu-Monette ZY, Zhang S, Li X, Manyam GC, Wang XX, Xia Y, Visco C, Tzankov A, Zhang L, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Parsons BM, Winter JN, Piris MA, Medeiros LJ, Young KH.

Aging (Albany NY). 2016 Feb;8(2):345-65.

36.

High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.

Marques SC, Ranjbar B, Laursen MB, Falgreen S, Bilgrau AE, Bødker JS, Jørgensen LK, Primo MN, Schmitz A, Ettrup MS, Johnsen HE, Bøgsted M, Mikkelsen JG, Dybkær K.

Exp Hematol. 2016 Apr;44(4):238-46.e2. doi: 10.1016/j.exphem.2015.12.007. Epub 2016 Feb 17.

PMID:
26854484
37.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.

Ye Q, Xu-Monette ZY, Tzankov A, Deng L, Wang X, Manyam GC, Visco C, Montes-Moreno S, Zhang L, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, Medeiros LJ, Hu S, Young KH.

Oncotarget. 2016 Jan 19;7(3):2401-16. doi: 10.18632/oncotarget.6262.

38.

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, Xia Y, Zhang L, Sun R, Visco C, Dybkaer K, Yin L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Parsons BM, Zhao X, Winter JN, Piris MA, McDonnell TJ, Miranda RN, Li Y, Medeiros LJ, Young KH.

Mod Pathol. 2015 Dec;28(12):1555-73. doi: 10.1038/modpathol.2015.118. Epub 2015 Nov 6.

39.

The application of human phase 0 microdosing trials: A systematic review and perspectives.

Svendsen P, El-Galaly TC, Dybkær K, Bøgsted M, Laursen MB, Schmitz A, Jensen P, Johnsen HE.

Leuk Lymphoma. 2016;57(6):1281-90. doi: 10.3109/10428194.2015.1101097. Epub 2015 Nov 16. Review.

PMID:
26428262
40.

Long Noncoding RNA Expression during Human B-Cell Development.

Petri A, Dybkær K, Bøgsted M, Thrue CA, Hagedorn PH, Schmitz A, Bødker JS, Johnsen HE, Kauppinen S.

PLoS One. 2015 Sep 22;10(9):e0138236. doi: 10.1371/journal.pone.0138236. eCollection 2015.

41.

Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma.

Li L, Xu-Monette ZY, Ok CY, Tzankov A, Manyam GC, Sun R, Visco C, Zhang M, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Møller MB, Wang J, Parsons BM, Winter JN, Piris MA, Pham LV, Medeiros LJ, Young KH.

Oncotarget. 2015 Sep 15;6(27):23157-80.

42.

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium.

Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, Huh J, Zhang L, Zhai Q, Wang Y, Qiu L, Dybkær K, Chiu A, Perry AM, Zhang S, Tzankov A, Rao H, Abramson J, Sohani AR, Xu M, Hsi ED, Zhu J, Ponzoni M, Wang S, Li L, Zhang M, Ferreri AJ, Parsons BM, Li Y, Piris MA, Medeiros LJ, Young KH.

Leukemia. 2016 Feb;30(2):361-72. doi: 10.1038/leu.2015.237. Epub 2013 Aug 26.

PMID:
26308769
43.

Investigation of Human Cancers for Retrovirus by Low-Stringency Target Enrichment and High-Throughput Sequencing.

Vinner L, Mourier T, Friis-Nielsen J, Gniadecki R, Dybkaer K, Rosenberg J, Langhoff JL, Cruz DF, Fonager J, Izarzugaza JM, Gupta R, Sicheritz-Ponten T, Brunak S, Willerslev E, Nielsen LP, Hansen AJ.

Sci Rep. 2015 Aug 19;5:13201. doi: 10.1038/srep13201.

44.

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.

Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Møller MB, Piris MA, Winter JN, O'Malley DP, Medeiros LJ, Young KH.

Mod Pathol. 2015 Oct;28(10):1297-314. doi: 10.1038/modpathol.2015.94. Epub 2015 Aug 7.

45.

Erratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH.

Oncotarget. 2015 Jun 10;6(16):14720. No abstract available.

46.

Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions.

Ok CY, Xu-Monette ZY, Li L, Manyam GC, Montes-Moreno S, Tzankov A, Visco C, Dybkær K, Routbort MJ, Zhang L, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM, Rao H, Møller MB, Winter JN, Piris MA, Wang SA, Medeiros LJ, Young KH.

Mod Pathol. 2015 Sep;28(9):1202-13. doi: 10.1038/modpathol.2015.76. Epub 2015 Jun 26.

47.

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma--is it necessary?

Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X, Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L, Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young KH.

Oncotarget. 2015 Jun 10;6(16):13933-45.

48.

MicroRNAs as novel biomarkers in diffuse large B-cell lymphoma--a systematic review.

Jørgensen LK, Poulsen MØ, Laursen MB, Marques SC, Johnsen HE, Bøgsted M, Dybkær K.

Dan Med J. 2015 May;62(5). pii: A5048. Review.

PMID:
26050834
49.

Inherited variation in immune response genes in follicular lymphoma and diffuse large B-cell lymphoma.

Nielsen KR, Steffensen R, Haunstrup TM, Bødker JS, Dybkær K, Baech J, Bøgsted M, Johnsen HE.

Leuk Lymphoma. 2015;56(12):3257-66. doi: 10.3109/10428194.2015.1058936. Epub 2015 Jul 7. Review.

PMID:
26044172
50.

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.

Falgreen S, Dybkær K, Young KH, Xu-Monette ZY, El-Galaly TC, Laursen MB, Bødker JS, Kjeldsen MK, Schmitz A, Nyegaard M, Johnsen HE, Bøgsted M.

BMC Cancer. 2015 Apr 8;15:235. doi: 10.1186/s12885-015-1237-6.

Supplemental Content

Loading ...
Support Center